China channel feed

For­eign in­vestors fled Chi­nese biotech af­ter the pan­dem­ic. They still haven’t come back

Last year
Financing

US-Chi­na ten­sions threat­en to en­snare ad­di­tion­al Chi­nese bio­phar­ma con­trac­tors

Last year
Pharma
Manufacturing

WuXi builds out lob­by­ing bench amid leg­isla­tive ef­fort to black­list com­pa­ny

Last year
Pharma
FDA+

Three more I-Mab ex­ecs ex­it af­ter US/Chi­na op­er­a­tions split

Last year
People

Con­gress' Chi­na hawks seek to add biotech sup­pli­ers to Pen­ta­gon warn­ing list

Last year
FDA+

Up­dat­ed: US in­tel­li­gence of­fi­cials told Con­gress that WuXi trans­ferred IP to Chi­nese au­thor­i­ties — re­port

Last year
Pharma

WuXi AppTec, WuXi Bi­o­log­ics con­tin­ue to build out US pres­ence de­spite po­lit­i­cal ten­sions 

Last year
Manufacturing

Hunt­ing for ‘cer­tain­ty and sta­bil­i­ty,’ WuXi Bio spot­lights client re­la­tion­ships

Last year
Manufacturing

The US could up­end bio­phar­ma man­u­fac­tur­ing. WuXi ri­vals have an open­ing

Last year
In Focus
Manufacturing

Nu­va­tion inks all-stock deal for US-Chi­na on­col­o­gy biotech An­Heart

Last year
Startups
Deals

Lead House spon­sor of WuXi-linked bill to leave Con­gress ear­ly

Last year
People
Pharma

Sen­ate opens probe in­to how high-risk re­search pos­es na­tion­al se­cu­ri­ty threats

Last year
Pharma

No­vo Nordisk bol­sters op­er­a­tions in Chi­na with $556M ex­pan­sion project

Last year
Pharma
Manufacturing

WuXi AppTec's 2023 sales large­ly re­liant on the US, re­port says

Last year
Manufacturing

Af­ter years of de­lay, BeiGene fi­nal­ly lands FDA ap­proval for its PD-1 drug

Last year
Pharma
FDA+

BeiGene looks be­yond Chi­na as it se­cures new API source, nears open­ing of US site

Last year
Manufacturing

BIO to cut ties with WuXi af­ter trade group was ac­cused of act­ing as a for­eign agent

Last year
Pharma

WuXi be­came a crit­i­cal part­ner to bio­phar­ma com­pa­nies. They’re not ready if the US cracks down

Last year
Deals
In Focus

Star­tups raised mil­lions to in-li­cense drugs to Chi­na. Then the mod­el fell apart

Last year
Deals
In Focus

Law­mak­ers call for 'line in the sand' be­tween US and Chi­nese biotech com­pa­nies

Last year
Pharma
Law

Sen­ate com­mit­tee ad­vances bill tar­get­ing Chi­nese man­u­fac­tur­ers as BIO faces at­tack for back­ing WuXi

Last year
Pharma
Manufacturing

Join­ing con­gres­sion­al skep­ti­cism of Chi­na's role in biotech, Biden ex­ec­u­tive or­der tar­gets da­ta pri­va­cy is­sues

Last year
Law

Chi­nese API man­u­fac­tur­er re­ceives FDA warn­ing let­ter af­ter QC em­ploy­ee says test re­sults 'in my mind'

Last year
FDA+
Manufacturing

Law­mak­ers’ ex­plo­sive charges turn a glob­al spot­light on Chi­na’s WuXi, and it’s feel­ing the heat

Last year
Bioregnum
First page Previous page 567891011 Next page Last page
A service from the Financial Times